IP Library Assignment 028381/0296
Patent Assignment
Reel/Frame 028381/0296

Assignment of Assignor's Interest

Recorded: 2012-06-15 Pages: 8
Assignors
BUKHALID, RAGHIDA
Executed: 2012-06-12
NIELSEN, ULRIK
Executed: 2012-06-12
WERNER, SHANNON
Executed: 2012-06-12
KEARNS, JEFFREY DAVID
Executed: 2012-06-13
Assignee
MERRIMACK PHARMACEUTICALS, INC.
ONE KENDALL SQUARE, SUITE B7201, CAMBRIDGE, MASSACHUSETTS, 02139
Covered Properties (2)
Methods of Treatment of Tumors Expressing Predominantly High Affinity Egfr Ligands or Tumors Expressing Predominantly Low Affinity Egfr Ligands with Monoclonal and Oglioclonal Anti-Egfr Antibodies
Patent: 8,691,231 →
Application: 13/488,270 →
Publication: US 2012/0308576
Methods and Kits for Predicting Tumor Responses to Antibodies Against Epidermal Growth Factor Receptor (Egfr) and Uses Thereof
Application: 61/493,252 →
Related Assignments (2)
Other recorded transfers of the patents in this record — the chain of ownership.
Security Interest Dec 28, 2015
From: MERRIMACK PHARMACEUTICALS, INC.
To: U.S. BANK NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 037394/0285 →
Release of Security Interest Apr 14, 2017
From: U.S. BANK NATIONAL ASSOCIATION
To: MERRIMACK PHARMACEUTICALS, INC.
Reel/Frame 042254/0349 →